You are here

MetalloPharm

Company Information
Address
1790 Riverstone Drive
Delaware, OH 43015-7085
United States



Information

UEI: N/A

# of Employees: 4


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Rapid point-of-care diagnosis of wound infection

    Amount: $224,974.00

    DESCRIPTION provided by applicant In the United States chronic wounds represent a major public health burden on patients as well as the health care economy Estimates put the number of chronic wou ...

    SBIRPhase I2016Department of Health and Human Services National Institutes of Health
  2. SBIR Phase I: A Diagnostic Device for Bacterial Detection

    Amount: $150,000.00

    The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to develop a simple general test strip that can be broadly used for the detection and chara ...

    SBIRPhase I2014National Science Foundation
  3. IGF::OT::IGF Capreomycin: Formulation for Oral Delivery

    Amount: $224,868.00

    Multidrug-resistant tuberculosis (MDR-TB) is an increasing challenge for the treatment of TB. Currently existing drugs for the treatment of MDR TB are only moderately potent, show restrictions with ab ...

    SBIRPhase I2014Department of Health and Human Services National Institutes of Health
  4. Novel Catalytic MetalloDrug Targeting IRES RNA for Treatment of HCV Infection

    Amount: $2,004,496.00

    DESCRIPTION (provided by applicant): HCV is responsible for 60% of the cases of chronic hepatitis and 50% of cases of cirrhosis, end- stage liver disease, and liver cancer. An effective vaccine has pr ...

    SBIRPhase II2011Department of Health and Human Services National Institutes of Health
  5. Metallodrugs Targeting HCV Protease

    Amount: $444,050.00

    DESCRIPTION (provided by applicant): Alcohol is a high risk factor in hepatitis C virus (HCV) infection and increases the severity of the infection. It has been estimated that 35% of alcohol-dependent ...

    SBIRPhase I2009Department of Health and Human Services National Institutes of Health
  6. Novel Engineered Synthetic Metallodrugs Directed Against HCV

    Amount: $156,722.00

    DESCRIPTION (provided by applicant): Alcohol is a high risk factor in hepatitis C virus (HCV) infection and increases the severity of the infection. It has been estimated that 35% of alcohol-dependent ...

    SBIRPhase I2007Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government